Skanska to sign contract for £330m AstraZeneca UK HQ


An artist's impression of the new facility.


Skanska is said to soon be signing a contract with pharmaceutical giant AstraZeneca for its £330m global headquarters which aims to be a world-renowned centre for life sciences. The firm’s global headquarters is currently in London and will move to Cambridge where this facility will be built.


It is anticipated that Skanska will sign a contract imminently to allow building work to commence in the spring.

Earlier this week, final planning was granted for the build which will be located on the Cambridge Biomedical Campus. When complete, it will become Astrazeneca’s largest centre for oncology research, as well as house scientists whose research focuses on cardiovascular and metabolic diseases, respiratory inflammation, autoimmune diseases and conditions of the nervous system.


The building was designed by Achitect Herzog & de Meuron, with reference to the historical buildings in Cambridge which are typically designed as low-rise buildings with a central courtyard.


Senior Partner, Stefan Marbach, said of the design: “The whole structure is connected in a single loop, providing short connections within the building and modern, innovative workspaces that support collaborative working.


“The saw-tooth” roof, which carries on throughout the façade, aims to unify the appearance of the building and give it a distinctive character.”


The site has a scheduled completion date of Q4 2016.